查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495454

腦性腎上腺腦白質營養不良市場：按類型、最終用戶分類 - 全球預測 2024-2030

Cerebral Adrenoleukodystrophy Market by Type (Diagnosis, Treatment), End-User (Home Care Services, Hospitals & Clinical, Specialty Clinics) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

腦性腎上腺腦白質營養不良市場規模預計2023年為53.6億美元，預計2024年將達到59.5億美元，2030年將達到112.9億美元，複合年成長率為11.21%。

腦性腎上腺腦白質營養不良 (CALD) 是一種罕見的性行為感染，主要影響神經系統和腎上腺（位於腎臟頂部的小器官）。 CALD 是腦白質營養不良的一種，是指一組以髓鞘變性為特徵的疾病，髓磷脂是大腦和脊髓中神經纖維周圍的保護鞘。提高對早期診斷的認知和篩檢將改善結果並推動對有效治療的需求。政府和監管機構透過資助和早期核准罕見疾病（包括 CALD）治療方法提供的支持正在推動市場向前發展。然而，基因治療和幹細胞移植等治療方法價格昂貴，因此市場拓展受到限制。此外，基因治療和幹細胞研究的技術進步提高了這些治療方法的功效和安全性，正在為市場創造重大機會。

主要市場統計
基準年[2023] 53.6億美元
預測年份 [2024] 59.5億美元
預測年份 [2030] 112.9億美元
複合年成長率（%） 11.21%

區域洞察

美洲地區在醫療保健和研究方面擁有強大的基礎設施，並採取了許多旨在早期發現和治療 CALD 的措施。一些國家新生兒篩檢計畫的進步加強了早期診斷，從而改善了受影響個體的長期預後。對基因療法和其他創新療法的投資正在顯示出有希望的結果，專利反映出標靶治療的持續改進。歐盟擁有強大的法律規範，支持廣泛的研究和新治療方法的採用。德國、法國和荷蘭等國家製定了積極的新生兒篩檢計劃，並在 CALD 相關研究和臨床試驗方面處於領先地位。歐洲藥品管理局 (EMA) 在加速創新治療方法的核准方面發揮關鍵作用。隨著阿拉伯聯合大公國和沙烏地阿拉伯等國家投資醫療基礎設施和專家培訓項目，中東地區對 CALD 的認知和資源不斷增加。亞太地區基因組學和生物技術領域正在快速發展，各國積極投資和資金籌措。亞太地區國家擁有強大的製藥業和政府支持的醫療保健系統，支持先進的研究和治療方法。

FPNV定位矩陣

FPNV 定位矩陣對於評估腦性腎上腺腦白質營養不良市場中供應商的定位至關重要。此矩陣提供了對供應商的全面評估，並檢查了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對腦性腎上腺腦白質營養不良市場供應商的當前狀態進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該領域競爭性質的寶貴見解，包括累積研究期、片段化優勢和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對腦腎上腺腦白質營養不良市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • CALD 的盛行率和診斷率不斷提高
      • 擴大醫療費用和保險範圍
    • 抑制因素
      • 高治療成本和進入問題
    • 機會
      • 藥物開發的進展
      • 改善基因治療以達到精準治療
    • 任務
      • 腦性腎上腺腦白質營養不良治療產品開發與製造的複雜性
  • 市場區隔分析
    • 類型：基因檢測的持續創新加速腦性腎上腺腦白質營養不良的診斷
    • 最終使用者：專科診所在持續管理和專業治療中發揮重要作用。
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章腦性腎上腺腦白質營養不良市場：依類型

  • 診斷
  • 治療

第7章腦性腎上腺腦白質營養不良市場：依最終用戶

  • 居家照護服務
  • 醫院和臨床
  • 專科診所

第8章北美及南美腦性腎上腺腦白質營養不良市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區腦性腎上腺腦白質營養不良市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲腦性腎上腺腦白質營養不良市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Neurocode 推出 ALZpath Dx 血液檢測，這是阿茲海默症診斷的突破
    • InSilicoTrials Technologies 與 Axoltis Pharma 之間的策略聯盟加強中樞神經系統藥物開發
    • FDA核准Lerigtazone 治療腦性腎上腺腦白質營養不良的 3 期 CALYX 研究
  • 戰略分析和建議

第12章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-CD5A9334D6B7

[181 Pages Report] The Cerebral Adrenoleukodystrophy Market size was estimated at USD 5.36 billion in 2023 and expected to reach USD 5.95 billion in 2024, at a CAGR 11.21% to reach USD 11.29 billion by 2030.

Cerebral adrenoleukodystrophy (CALD) is a rare genetic infection that mainly affects the nervous system and adrenal glands, which are small organs on top of each kidney. CALD is a type of leukodystrophy, which refers to a group of disorders characterized by the degeneration of myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. Increased awareness and better screening practices for early diagnosis can lead to improved outcomes, thereby driving the demand for effective treatments. Government and regulatory support through funding and fast-track approvals for treatments of rare diseases, including CALD, driving the market forward. However, the high cost associated with treatments such as gene therapy and stem cell transplantation limits the market expansion. Furthermore, technological advancements in gene therapy and stem cell research that increase the effectiveness and safety of these treatments pose significant opportunities to the market.

KEY MARKET STATISTICS
Base Year [2023] USD 5.36 billion
Estimated Year [2024] USD 5.95 billion
Forecast Year [2030] USD 11.29 billion
CAGR (%) 11.21%

Regional Insights

The American region exhibits a strong infrastructure in healthcare and research, with numerous initiatives aiming at early detection and treatment of CALD. Advances in newborn screening programs across several countries have enhanced early diagnosis, thereby improving the long-term prognosis of affected individuals. Investments in gene therapy and other innovative treatments have shown promising results, with patents reflecting ongoing improvements in targeted therapies. The EU has a strong regulatory framework that supports extensive research and the adoption of new therapies. Countries including Germany, France, and the Netherlands have active newborn screening programs and are leaders in research and clinical trials related to CALD. The European Medicines Agency (EMA) plays an important role in the rapid approval of innovative treatments. Awareness and resources for CALD are growing in the Middle East, with countries including the UAE and Saudi Arabia investing in healthcare infrastructure and specialist training programs. The APAC region is rapidly advancing in the fields of genomics and biotechnology, with substantial countries' investments & funding directed toward genetic research. The APAC countries with a strong pharmaceutical sector and government-backed healthcare system support advanced research and treatment methodologies.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Cerebral Adrenoleukodystrophy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increased prevalence and diagnostic rates of CALD
      • Growing healthcare expenditure and insurance coverage
    • Market Restraints
      • High cost of treatment and accessibility issues
    • Market Opportunities
      • Advancements in therapeutic product development
      • Improvements in gene therapy for precision treatment
    • Market Challenges
      • Product development and manufacturing complexities in cerebral adrenoleukodystrophy treatment
  • Market Segmentation Analysis
    • Type: Ongoing innovations in genetic testing to accelerate the diagnosis of cerebral adrenoleukodystrophy
    • End-User: Specialty clinics play a significant role in ongoing management and specialized treatments.
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cerebral Adrenoleukodystrophy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cerebral Adrenoleukodystrophy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Breakthrough in Alzheimer's Disease Diagnosis as Neurocode Launch ALZpath Dx Blood Test

Neurocode announced the clinical release of ALZpath Dx, a cutting-edge blood test designed to detect, diagnose, and monitor Alzheimer's disease (AD). This test measured the circulating levels of phosphorylated tau at position 217 (pTau217), a key biomarker for AD. Utilizing Quanterix Corp's Simoa(R) technology, ALZpath Dx offered a non-invasive, cost-effective, and highly accurate diagnostic alternative to traditional methods like brain imaging or cerebrospinal fluid tests. [Published On: 2024-03-04]

Strategic Collaboration between InSilicoTrials Technologies and Axoltis Pharma to Enhance CNS Drug Development

InSilicoTrials Technologieshas formed a strategic partnership with Axoltis Pharma, which is focused on advancing treatments for neurodegenerative conditions. This collaboration centers around employing InSilicoTrials Technologies's platform, particularly its InSilicoNEURO suite, to explore the effects of Axoltis Pharma's NX210c, a 12-amino acid peptide, on virtual patients with various Central Nervous System (CNS) disorders including Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease, and Multiple Sclerosis. [Published On: 2023-07-27]

FDA Approves Phase 3 CALYX Trial for Leriglitazone in Treatment of Cerebral Adrenoleukodystrophy

MINORYX THERAPEUTICS SL has gained approval from the US FDA for its Phase 3 CALYX trial, focusing on leriglitazone as a therapeutic option for adult male patients with cerebral Adrenoleukodystrophy (cALD), a subtype of X-linked Adrenoleukodystrophy (X-ALD). The primary study endpoint included major outcomes such as 'time to death' or 'permanent ventilatory support. Endpoints were built on favorable previous trial outcomes and ongoing compassionate use data. Leriglitazone has shown promise in halting lesion progression, achieving stabilizations paralleled to those seen in hematopoietic stem cell transplant or gene therapy treatments. [Published On: 2023-05-31]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cerebral Adrenoleukodystrophy Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cerebral Adrenoleukodystrophy Market, highlighting leading vendors and their innovative profiles. These include bluebird bio, Inc., Boston Scientific Corporation, Esaote S.p.A, FUJIFILM Corporation, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Medtronic PLC, MINORYX THERAPEUTIS SL, NeuroVia, Inc., Neusoft Corporation, POXEL SA, SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD., Shimadzu Corporation, Siemens AG, Stryker Corporation, and Toshiba Corporation.

Market Segmentation & Coverage

This research report categorizes the Cerebral Adrenoleukodystrophy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Diagnosis
      • Blood Tests
      • Genetic Testing
      • MRI
      • Neurological Tests
    • Treatment
      • Adrenal Hormone Replacement
      • Gene Therapy
      • Stem Cell Transplantation
  • End-User
    • Home Care Services
    • Hospitals & Clinical
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased prevalence and diagnostic rates of CALD
      • 5.1.1.2. Growing healthcare expenditure and insurance coverage
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and accessibility issues
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in therapeutic product development
      • 5.1.3.2. Improvements in gene therapy for precision treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Product development and manufacturing complexities in cerebral adrenoleukodystrophy treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Ongoing innovations in genetic testing to accelerate the diagnosis of cerebral adrenoleukodystrophy
    • 5.2.2. End-User: Specialty clinics play a significant role in ongoing management and specialized treatments.
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Cerebral Adrenoleukodystrophy Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnosis
  • 6.3. Treatment

7. Cerebral Adrenoleukodystrophy Market, by End-User

  • 7.1. Introduction
  • 7.2. Home Care Services
  • 7.3. Hospitals & Clinical
  • 7.4. Specialty Clinics

8. Americas Cerebral Adrenoleukodystrophy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cerebral Adrenoleukodystrophy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cerebral Adrenoleukodystrophy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Breakthrough in Alzheimer's Disease Diagnosis as Neurocode Launch ALZpath Dx Blood Test
    • 11.3.2. Strategic Collaboration between InSilicoTrials Technologies and Axoltis Pharma to Enhance CNS Drug Development
    • 11.3.3. FDA Approves Phase 3 CALYX Trial for Leriglitazone in Treatment of Cerebral Adrenoleukodystrophy
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CEREBRAL ADRENOLEUKODYSTROPHY MARKET RESEARCH PROCESS
  • FIGURE 2. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CEREBRAL ADRENOLEUKODYSTROPHY MARKET DYNAMICS
  • FIGURE 7. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. CEREBRAL ADRENOLEUKODYSTROPHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CEREBRAL ADRENOLEUKODYSTROPHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY BLOOD TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY MRI, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY MRI, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY NEUROLOGICAL TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY NEUROLOGICAL TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADRENAL HORMONE REPLACEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY ADRENAL HORMONE REPLACEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITALS & CLINICAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY HOSPITALS & CLINICAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA CEREBRAL ADRENOLEUKODYSTROPHY MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN CEREBRAL ADRENO